Literature DB >> 14684332

Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits.

Jean-Yves Winum1, Angela Casini, Francesco Mincione, Michele Starnotti, Jean-Louis Montero, Andrea Scozzafava, Claudiu T Supuran.   

Abstract

A series of N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines was prepared by reaction of sulfanilamide with different monosaccharides in the presence of ammonium chloride. The new compounds were investigated for inhibition of the metallo-enzyme carbonic anhydrase (CA, EC 4.2.1.1), involved in aqueous humor secretion within the mammalian eye. Isozymes CA I and CA II were strongly inhibited by some of these compounds, which showed inhibition constants in the range of 510-1200 nM against CA I and 10-25 nM against CA II, similarly to clinically used sulfonamides, such as acetazolamide, methazolamide, dichlorophenamide, dorzolamide and brinzolamide. The presence of sugar moieties in these molecules induced an enhanced water solubility as compared to other sulfonamides. In hypertensive rabbits (a widely used animal model of glaucoma), two of the new compounds showed strong and long-lasting intraocular pressure (IOP) lowering, being more effective than dorzolamide and brinzolamide, the two clinically used, topically acting antiglaucoma sulfonamides with CA inhibitory properties.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14684332     DOI: 10.1016/j.bmcl.2003.09.063

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

Review 1.  Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding.

Authors:  Vijay M Krishnamurthy; George K Kaufman; Adam R Urbach; Irina Gitlin; Katherine L Gudiksen; Douglas B Weibel; George M Whitesides
Journal:  Chem Rev       Date:  2008-03       Impact factor: 60.622

2.  Nanovesicular formulation of brimonidine tartrate for the management of glaucoma: in vitro and in vivo evaluation.

Authors:  Sabyasachi Maiti; Sayon Paul; Ranjit Mondol; Somasree Ray; Biswanath Sa
Journal:  AAPS PharmSciTech       Date:  2011-06-14       Impact factor: 3.246

3.  RES-loaded pegylated CS NPs: for efficient ocular delivery.

Authors:  Saravanakumar Pandian; Vinoth Jeevanesan; Chandrasekar Ponnusamy; Subramanian Natesan
Journal:  IET Nanobiotechnol       Date:  2017-02       Impact factor: 1.847

4.  Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide.

Authors:  John Youshia; Amany O Kamel; Abdelhameed El Shamy; Samar Mansour
Journal:  Int J Nanomedicine       Date:  2012-05-17

5.  PEG Linker Length Strongly Affects Tumor Cell Killing by PEGylated Carbonic Anhydrase Inhibitors in Hypoxic Carcinomas Expressing Carbonic Anhydrase IX.

Authors:  Utpal K Mondal; Kate Doroba; Ahmed M Shabana; Rachel Adelberg; Md Raqibul Alam; Claudiu T Supuran; Marc A Ilies
Journal:  Int J Mol Sci       Date:  2021-01-23       Impact factor: 5.923

6.  Development of dorzolamide loaded 6-o-carboxymethyl chitosan nanoparticles for open angle glaucoma.

Authors:  Ujwala Shinde; Mohammed Hadi Ahmed; Kavita Singh
Journal:  J Drug Deliv       Date:  2013-10-10

7.  Design, synthesis and biological evaluation of carbohydrate-based sulphonamide derivatives as topical antiglaucoma agents through selective inhibition of carbonic anhydrase II.

Authors:  Zhuang Hou; Chuanchao Li; Yichuang Liu; Miao Zhang; Yitong Wang; Zhanfang Fan; Chun Guo; Bin Lin; Yang Liu
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 8.  Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review.

Authors:  Marcelo Luís Occhiutto; Raul C Maranhão; Vital Paulino Costa; Anastasios G Konstas
Journal:  Adv Ther       Date:  2019-12-10       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.